AHA: Apixaban Beneficial for Patients With Subclinical A-Fib
TUESDAY, Nov. 14, 2023 -- Apixaban results in a lower risk for stroke or systemic embolism than aspirin for patients with subclinical atrial fibrillation, according to a study published online Nov. 12 in the New England Journal of Medicine to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 14, 2023 Category: Pharmaceuticals Source Type: news
Late-Breaking Data Show an Aspirin-Free Medication Regimen Benefits People with Abbott's HeartMate 3 ™ Heart Pump
(Source: Abbott.com)
Source: Abbott.com - November 13, 2023 Category: Pharmaceuticals Source Type: news
Dropping Aspirin Cuts Bleeding in LVAD Patients Dropping Aspirin Cuts Bleeding in LVAD Patients
A randomized trial evaluating vitamin K therapy with aspirin or placebo with a left ventricular assist device shows avoiding aspirin reduced bleeding without increasing thrombotic risk.Medscape Medical News (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - November 13, 2023 Category: Transplant Surgery Tags: Cardiology News Source Type: news
Dropping Aspirin Cuts Bleeding in LVAD Patients Dropping Aspirin Cuts Bleeding in LVAD Patients
A randomized trial evaluating vitamin K therapy with aspirin or placebo with a left ventricular assist device shows avoiding aspirin reduced bleeding without increasing thrombotic risk.MDedge News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - November 13, 2023 Category: Internal Medicine Tags: Cardiology News Source Type: news
No Aspirin Needed After LVAD, ARIES-HM3 Trial Says
(MedPage Today) -- PHILADELPHIA -- Dropping aspirin from the antithrombotic regimen after HeartMate 3 left ventricular assist device (LVAD) implantation appeared safer than the usual combination approach in the ARIES-HM3 trial.
Atop warfarin... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 12, 2023 Category: Cardiology Source Type: news
Weight Loss Drug Wegovy Can Also Reduce Risk of Serious Heart Events, Study Shows
Popular weight loss drugs have dominated news headlines and social media, mostly for their ability to help people shed pounds and control diabetes. But now there is evidence that one of the drugs, semaglutide, can also help reduce the risk of dying from heart disease in some patients. The drug semaglutide is sold under the brand names Wegovy, Ozempic, and Rybelsus. This trial, however, only studied the effects of Wegovy, which is semaglutide at 2.4mg in injectable form, and currently approved for weight management. The results of a much-anticipated study, sponsored by semaglutide’s maker Novo Nordisk, investigating t...
Source: TIME: Health - November 11, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthscienceclimate Source Type: news
Why is pre-eclampsia still causing the deaths of mothers and their babies?
The condition affects up to 6% of all pregnancies yet understanding of its causes and how to treat it remains basicHaving had one normal pregnancy, Emma Bailey assumed that her second experience of childbirth would progress relatively smoothly. But, at 34 weeks, she began to suffer sudden bursts of stabbing pain just underneath her ribcage.“It was really excruciating pain,” she remembers. “I was admitted to hospital, but they sent me home, saying it was probably just anxiety. I then had to be readmitted the very next day because I was in agony.”Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - November 11, 2023 Category: Science Authors: David Cox Tags: Science Pregnancy Health Maternal mortality Stroke Heart attack High blood pressure Infant and child mortality UK news Aspirin Parents and parenting Medical research Bill and Melinda Gates Foundation Source Type: news
No Harm in Short Aspirin Duration After PCI for ACS No Harm in Short Aspirin Duration After PCI for ACS
Less than a month of ticagrelor plus aspirin therapy followed by ticagrelor alone for 1 year after PCI for ACS was noninferior to dual antiplatelet therapy in the T-PASS trial.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - November 8, 2023 Category: Intensive Care Tags: Cardiology News Source Type: news
ACG: Prophylactic Low-Dose Aspirin in Pregnancy Does Not Increase IBD Activity
THURSDAY, Oct. 26, 2023 -- Use of low-dose aspirin (LDA) among pregnant women with inflammatory bowel disease (IBD) is not associated with an increased risk for disease activity, according to a study presented at the annual meeting of the American... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 26, 2023 Category: Pharmaceuticals Source Type: news
Even Less Aspirin With Ticagrelor-Based DAPT Safe After Stenting for ACS
(MedPage Today) -- SAN FRANCISCO -- For ticagrelor-based antithrombotic regimens after drug-eluting stent implantation for acute coronary syndrome (ACS), stopping aspirin within the first month appeared to be safer than continuing it in the T... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - October 26, 2023 Category: Cardiology Source Type: news
Call for Requests for NLM Traveling Exhibitions: Open Through October 31st
NLM has opened the next Call for Requests for Traveling Exhibitions on October 17. At that time, you can request two new titles with booking dates from April 2024 to August 2025:
Promising Future, Complex Past: Artificial Intelligence and the Legacy of Physiognomy
“Take two and call me in the morning.”: The Story of Aspirin Revisited
When: Oct 17 at 1pm CT to Oct 31 at 1pm CT
During the Call for Requests, use an online Request Form to submit your requests.
How: Online submission and Lottery selected bookings
The online Request Form accepts submissions only during the period when the Call is open. Afterwards, ...
Source: The Cornflower - October 20, 2023 Category: Databases & Libraries Authors: Miles Dietz-Castel Tags: Blog Source Type: news
Enteric-Coated, Uncoated Aspirin Have Similar Effectiveness in Heart Patients
WEDNESDAY, Oct. 11, 2023 -- There is no significant difference in the primary effectiveness or safety between enteric-coated aspirin and uncoated aspirin among patients with cardiovascular disease, according to a study published online Oct. 4 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 11, 2023 Category: Pharmaceuticals Source Type: news
No Benefit of Enteric-Coated Aspirin vs Uncoated in CVD No Benefit of Enteric-Coated Aspirin vs Uncoated in CVD
There is no decrease in efficacy but no significant benefit of enteric-coated aspirin over uncoated aspirin in patients with cardiovascular disease, post hoc results of the ADAPTABLE trial suggest.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 5, 2023 Category: Neurology Tags: Cardiology News Source Type: news
Aspirin Outcomes No Different With Safety Coating
(MedPage Today) -- An enteric coating did not hurt the effectiveness of aspirin pills for secondary prevention of atherosclerotic cardiovascular disease (ASCVD), but it didn't make it any safer either, researchers found in the ADAPTABLE trial... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - October 4, 2023 Category: Cardiology Source Type: news
Safer and More Precise Management of Osteoarthritis Pain Safer and More Precise Management of Osteoarthritis Pain
A new study suggests that to reduce the risk of cardiovascular events, the choice of NSAID in patients with osteoarthritis should be informed by whether or not they are concurrently using aspirin.American Journal of Epidemiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 22, 2023 Category: Consumer Health News Tags: Internal Medicine Journal Article Source Type: news
